Fig. 8: The safety assessment of the triple combination treatment (iRFA + LTX-315 + anti-CTLA-4 antibody) for HCC. | Cell Death & Disease

Fig. 8: The safety assessment of the triple combination treatment (iRFA + LTX-315 + anti-CTLA-4 antibody) for HCC.

From: Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma

Fig. 8: The safety assessment of the triple combination treatment (iRFA + LTX-315 + anti-CTLA-4 antibody) for HCC.The alternative text for this image may have been generated using AI.

A The typical HE-stained images of heart, liver, spleen, lung, and kidney tissues in five groups suggested that the triple combination treatment did not cause damage to the major organs. B–E Two liver function parameters, i.e., ALT and AST, were in the normal range in the triple combination treatment group, and were significantly lower than those in the control and iRFA groups. n = 6 in each group. Error bars represent standard deviation. ns represents no statistically significant difference. ***p < 0.001. iRFA incomplete radiofrequency ablation, CTLA-4 cytotoxic T lymphocyte antigen-4, HCC hepatocellular carcinoma, H&E Hematoxylin and eosin, ALT glutamic pyruvic transaminase, AST glutamic oxaloacetic transaminase.

Back to article page